Skip to Main Content

Coverage and Billing Guidance for Biomarker Testing

Date: 01/26/26

Sunshine Health covers biomarker testing in alignment with the Agency for Health Care Administration (AHCA) policy.

AHCA updated the Medicaid Laboratory Services Coverage Policy to include coverage of biomarker testing effective June 1, 2025.

Biomarker tests require prior authorization and are reviewed for medical necessity.

The Practitioner Laboratory Fee Schedule added 632 biomarker test codes with pricing information effective July 1, 2025. The January 1, 2026, Medicaid fee schedule will cover additional codes for a total of 941 biomarker test codes, per AHCA.

What Are Biomarker Tests?

Laboratory tests samples of blood, tissue or other bodily fluids to check for certain genes, proteins or other molecules for the purposes of:

  • Diagnosing a patient for a condition or disease
  • Determining their risk of developing a condition or disease
  • Determining how they may respond to treatment
  • Managing their treatment
  • After a diagnosis, determining the risk

Biomarker Codes

  • CPT® Codes (Current Procedural Terminology): Common molecular and genetic tests
  • PLA Codes (Proprietary Laboratory Analyses): A specific company’s lab tests
  • MAAA Codes (Multianalyte Assays with Algorithmic Analyses): Multiple biomarkers run through a mathematical algorithm

Biomarker Resources

This Guidance Applies to These Products

  • Sunshine Health Medicaid (MMA)
  • Comprehensive Long Term Care (LTC)
  • Sunshine Health Pathway to Shine Child Welfare Specialty Plan (CWSP)
  • Sunshine Health Mindful Pathways Serious Mental Illness Specialty Plan (SMI)
  • Sunshine Health Power to Thrive HIV/AIDS Specialty Plan (HIV)

Questions?

Sunshine Health has a wealth of resources available to help answer your questions and address your concerns:

SH_11349